Gain Therapeutics
GANX
GANX
42 hedge funds and large institutions have $15.8M invested in Gain Therapeutics in 2026 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 9 increasing their positions, 10 reducing their positions, and 15 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
less ownership
Funds ownership: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less funds holding
Funds holding: →
33% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 15
39% less capital invested
Capital invested by funds: $25.9M → $15.8M (-$10.1M)
Holders
42
Holding in Top 10
–
Calls
$502K
Puts
$100K
Top Buyers
| 1 | +$635K | |
| 2 | +$303K | |
| 3 | +$286K | |
| 4 |
Marshall Wace
London,
United Kingdom
|
+$234K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$107K |
Top Sellers
| 1 | -$551K | |
| 2 | -$251K | |
| 3 | -$179K | |
| 4 |
Jones Financial Companies
Des Peres,
Missouri
|
-$154K |
| 5 |
OAC
OMERS Administration Corp
Toronto,
Ontario, Canada
|
-$120K |
